Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer’s disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Finkel S, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment.Int Psychogeriatr 1996; 8 (Suppl 3): 497–500.
Reisberg B, Monteiro I, Boksay I, Auer S, Torossian C, Kenowsky S. Do many of the behavioral and psychological symptoms of dementia constitute a distinct clinical syndrome? Current evidence using the BEHAVE-AD.Int Psychogeriatr 2000; 12: 155–164.
Reisberg B, Ferris S, Torossian C, Kluger A, Montriro I. Pharmacologic Treatment of Alzheimer’s Disease: A Methodologic Critique Based Upon Current Knowledge of Symptomatology and Relevance for Drug Trials.Int Psychogeriatr 1992; 4 (Suppl 1): 9–42.
Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment.J Clin Psychiatr 1987; 48 (Suppl 5): 9–15.
Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi D, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.Neurology 1994; 44 (12): 2308–2314.
Monteiro IM, Boksay I, Auer SR, Torossian C, Ferris SH, Reisberg B. Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer’s disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability.Eur Psychiatr 2001; 16: 5S-24S.
Asada T, Honma A, Kimura M, Uno M. The reliability of Japanese version of BEHAVE-AD scale.Japanese Journal of Geriatric Psychiatry (JPN) 1999; 10 (7): 825–834.
Meguro K, Ueda M, Yamaguchi T, Sekita Y, Yamazaki H, Oikawa Y, et al. Disturbance in Daily Sleep/Wake Patterns in Patients with Cognitive Impairment and Decreased Daily Activity.J Am Geriatr Soc 1990; 38: 1176–1182.
Meguro K, Ueda M, Kobayashi I, Yamaguchi S, Yamazaki H, Oikawa Y, et al. Sleep Disturbance in Elderly Patients with Cognitive Impairment, Decreased Daily Activity and Periventricular White-Matter Lesions.Sleep 1995; 18 (2): 109–114.
Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, et al. Reduced striatal dopamine receptors in Alzheimer’s disease: Single photon emission tomography study with the D-2 tracer I-123-IBZM.Neurology 1996; 47 (4): 1065–1068.
Meguro K, Itoh M, Yanai K, Takase K, Yamaguchi S, Ido T, et al. Psychiatric wandering behavior in dementia patients correlated with increased striatal dopamine D-2 receptor as shown by [C-11]YM-09151-2 and positron emission tomography.Eur J Neurol 1997; 4 (3): 221–226.
Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, et al. Frontal lobe hypometabolism and depression in Alzheimer’s disease.Neurology 1998; 50 (2): 380–383.
Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Cerebral correlates of psychotic symptoms in Alzheimer’s disease.J Neurol Neurosurg Psychiatr 2000; 69 (2): 167–171.
Sunderland T. Cholinergic contributions to behavioral disturbances in Alzheimer’s disease.Int Psychogeriatr 2000; 12: 231–235.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease.Neurology 1984; 34 (7): 939–944.
Granger CV, Albrecht GL, Hamilton BB. Outcome of comprehansive medical rehabilitation—measurement by pulses profile and the Barthel Index.Arch Phys Med Rehab 1979; 60 (4): 145–154.
McKeith I, Galasko D, Kosaka K, Perry E, Dickson D, Hansen L, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.Neurology 1996; 47 (5): 1113–1124.
Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Hogberg T, et al. Stereoselective binding of11C-raclopride in living human brain—a search for extrastriatal central D2-dopamine receptors by PET.Psychopharmacology (Berl) 1988; 94 (4): 471–478.
Mintun MA, Raichle ME, Kibourn MR, Wooten GF, Welch MJ. A quantitative model for thein vivo assessment of drug binding sites with positron emission tomography.Ann Neurol 1984; 15 (3): 217–227.
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data.J Cereb Blood Flow Metab 1996; 16 (5): 834–840.
Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D-2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia.Am J Psychiatry 2000; 157 (4): 514–520.
Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, et al. Dose-Dependent Occupancy of Central Dopamine-D(2) Receptors by the Novel Neuroleptic Cp-88,059-01—a Study Using Positron Emission Tomography and C-11 Raclopride.Psychopharmacology 1993; 112 (2–3): 308–314.
Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography.Proc Natl Acad Sci USA 1985; 82 (11): 3863–3867.
Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.Science 1986; 231 (4735): 258–261.
Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.Am J Psychiatry 1999; 156 (2): 286–293.
Reisberg B, Franssen E, Sclan S, Kluger A, Ferris S. Stage Specific Incidence of Potentially Remediable Behavioral Symptoms in Aging and Alzheimer Disease; A study of 120 Patients Using the Behave-AD.Bull Clin Neurosci 1989; 54: 95–112.
Eustace A, Coen R, Walsh C, Cunningham CJ, Walsh JB, Coakley D, et al. A longitudinal evaluation of behavioral and psychological symptoms of probable Alzheimer’s disease.Int J Geriatr Psychiatr 2002; 17 (10): 968–973.
Terai M, Hidaka K, Nakamura Y. Comparison of [H-3] Ym-09151-2 with [H-3] Spiperone and [H-3] Raclopride for Dopamine D-2 Receptor-Binding to Rat Striatum.Eur J Pharmacol 1989; 173 (2–3): 177–182.
Ishiwata K, Ogi N, Hayakawa N, Umegaki H, Nagaoka T, Oda K, et al. Positron emission tomography andex vivo andin vitro autoradiography studies on dopamine D2-like receptor degeneration in the quinolinic acid-lesioned rat striatum: comparison of [11C]raclopride, [11C]nemonapride and [11C]N-methylspiperone.Nucl Med Biol 2002; 29 (3): 307–316.
Rinne JO, Sahlberg N, Ruottinen H, Nagren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer’s disease assessed by positron emission tomography.Neurology 1998; 50 (1): 152–156.
Kemppainen N, Ruottinen H, Nagren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.Neurology 2000; 55 (2): 205–209.
Willner P, Phillips G, Muscat R, Suppression of Rewarded Behavior by Neuroleptic Drugs: Can’t or Won’t, and Why? inThe Mesolimbic Dopamine System: From Motivation to Action, Willner P, Scheel-Kruger J (eds), John Wiley & Sons, 1991: 251–271.
Willner P, Muscat R, Papp M, Sampson D. Dopamine, Depression and Anti-Depressant Drugs, inThe Mesolimbic Dopamine System: From Motivation to Action, Willner P, Scheel-Kruger J (eds), John Wiley & Sons, 1991: 387–410.